Salix Pharmaceuticals, Ltd. Share Price

Stocks

17/15/17	Endo : Valeant trumps Endo with $10.96 billion bid for Salix Pharma	RE
17/15/17	Bank of Montreal : TSX climbs on upbeat sentiment ahead of Fed meeting	RE
17/15/17	Wall St. bounces as dollar drops, Fed worries ease	RE
16/15/16	Endo : withdraws offer for Salix	RE
12/15/12	Valeant Pharmaceuticals Intl : TSX rebounds as energy shares advance with oil price	RE
05/15/05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/15/05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/15/05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
24/15/24	Shire : buys Meritage Pharma for at least $70 million	RE
24/15/24	Canadian Natural Resources : TSX gains on Valeant news; financial stocks weigh	RE
24/15/24	Boeing : Nasdaq ends up 9th session; S&P 500, Dow dip with energy	RE
23/15/23	BioMarin Pharmaceutical : Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources	RE
22/15/22	Salix Pharmaceuticals : Valeant nears deal to buy Salix for about $10 billion - WSJ	RE

12/15/12	Salix Pharmaceuticals : Confirms Receipt of an Unsolicited Proposal from Endo International plc	BU
03/15/03	Salix Pharmaceuticals : Reports 4Q2014 and FY2014 Results	BU
27/15/27	Salix Pharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
26/15/26	Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 1.5% Convertible Senior Notes Due 2019	BU
26/15/26	Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 2.75% Convertible Senior Notes Due 2015	BU

02/15/02	Valeant Pharmaceuticals Intl : Le laboratoire canadien Valeant conclut l'acquisition de Salix
30/15/30	Sanofi ne juge pas des acquisitions "indispensables"-Pdt
17/15/17	Le recul du dollar a favorisé le rebond de Wall Street
16/15/16	Allergan : Valeant relève son offre sur Salix, Endo jette l'éponge
16/15/16	BlackBerry : Les valeurs à suivre sur les marchés américains

Manager	Title	Age	Since
Josh Coyle SAM	Sales & Marketing	-	01/01/2018
John Temperato SAM	Sales & Marketing	61	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALIX PHARMACEUTICALS, LTD.	-.--%	+0.16%	-	-	0
ELI LILLY AND COMPANY	+6.24%	+4.54%	+67.92%	+141.47%	1,14800Cr
JOHNSON & JOHNSON	+1.33%	+2.52%	+47.03%	+86.59%	65TCr
ABBVIE INC.	+1.07%	+1.20%	+28.19%	+103.40%	51TCr
ROCHE HOLDING AG	+0.73%	+2.45%	+54.26%	+66.47%	38TCr
MERCK & CO., INC.	+4.23%	-0.80%	+68.69%	+42.24%	35TCr
NOVARTIS AG	+2.38%	+2.65%	+34.31%	+56.33%	29TCr
ASTRAZENECA PLC	+2.26%	+0.55%	+3.92%	+27.74%	26TCr
AMGEN INC.	+1.88%	+2.59%	+57.26%	+74.34%	24TCr
GILEAD SCIENCES, INC.	+1.87%	+2.76%	+36.32%	+107.71%	20TCr
Average	+2.23%	+1.39%	+44.21%	+78.48%	44.86TCr
Weighted average by Cap.	+3.11%	+1.50%	+49.52%	+92.82%